Loading…
Sutro Biopharma, Inc. is projected to rise to $40.53 by 2027, a +35% move from its current price of $29.99. STRO is currently trading below its 50-day average (a bearish sign). Technical indicators currently lean buy.
A data-driven summary — not financial advice. See the full breakdown below.
Live market data via Yahoo Finance · updated 7/11/2026
| Period | Min | Prediction | Max | Change |
|---|---|---|---|---|
| Jul 13 | $28.70 | $30.02 | $31.41 | +0.11% |
| Jul 14 | $28.19 | $30.05 | $32.04 | +0.21% |
| Jul 15 | $27.82 | $30.09 | $32.53 | +0.32% |
| Jul 16 | $27.52 | $30.12 | $32.97 | +0.43% |
| Jul 17 | $27.25 | $30.15 | $33.36 | +0.54% |
| Jul 18 | $27.02 | $30.18 | $33.71 | +0.64% |
| Jul 19 | $26.81 | $30.22 | $34.05 | +0.75% |
| Period | Min | Prediction | Max | Change |
|---|---|---|---|---|
| Week 1 | $26.81 | $30.22 | $34.05 | +0.75% |
| Week 2 | $25.71 | $30.44 | $36.05 | +1.51% |
| Week 3 | $24.94 | $30.67 | $37.73 | +2.27% |
| Week 4 | $24.33 | $30.90 | $39.25 | +3.04% |
| Week 5 | $23.83 | $31.14 | $40.67 | +3.82% |
| Week 6 | $23.41 | $31.37 | $42.04 | +4.60% |
| Week 7 | $23.04 | $31.61 | $43.36 | +5.39% |
Short-term targets derived from the forecast trend and recent volatility. Highly uncertain — not financial advice.
Sutro Biopharma, Inc. operates as an oncology company. The company develops site-specific and novel-format antibody drug conjugates (ADCs) that enables its proprietary integrated cell-free protein synthesis platform, XpressCF; and site-specific conjugation platform, XpressCF+.
Its lead product candidate includes STRO-004, a tissue factor (TF) targeting ADC for the treatment of TF-expressing solid tumors, including non-small cell lung cancer, head and neck squamous cell carcinoma, cervical cancer, colorectal cancer, pancreatic ductal adenocarcinoma, endometrial cancer, and bladder cancer.
The company also develops VAX-24 and Vax-31 pneumococcal conjugate vaccine candidates that is in Phase II/III clinical trials for the treatment of invasive pneumococcal disease in adults and adults and infants; and STRO-003, an ADC directed against an anti-receptor tyrosine kinase-like orphan receptor 1 (ROR1) for the treatment of solid tumors, such as triple negative breast cancer, non-small cell lung cancer, and ovarian cancer, as well as hematological cancers.
Sutro Biopharma has collaboration and license agreements with Vaxcyte to discover and develop vaccine candidates for the treatment or prophylaxis of infectious diseases; Tasly Biopharmaceuticals Co., Ltd. to develop and commercialize STRO-002 in Greater China; Ipsen to develop and commercialize STRO-003, an ADC targeting ROR1; and Astellas Pharma Inc. to develop immunostimulatory ADC.
The company was formerly known as Fundamental Applied Biology, Inc. Sutro Biopharma, Inc. was incorporated in 2003 and is headquartered in South San Francisco, California.
Sutro Biopharma, Inc. (STRO) trades at $30.24 with a market cap of $501.09M and is ranked 3073 by market capitalization. The stock operates within the Healthcare sector. The current price and surrounding fundamentals position the company as a biotech-focused oncology player with several ADC and vaccine programs in development.
The long-range forecast shows a potential for substantial upside, with the average price projected to rise meaningfully by 2030 and beyond. The all-time price trajectory remains contingent on clinical and regulatory progress, as with many biotech names, but the projected path indicates meaningful upside over the coming years.
A major floor 34.3% below — a decisive break under it would weaken the trend.
The nearest floor, 18.5% below — buyers have tended to step in here.
The nearest ceiling, 11.2% above — a clean break opens room to run.
A major ceiling 36.4% above — clearing it would confirm fresh momentum.
Key STRO support and resistance from recent price action — levels where the trend has historically paused or reversed. Percentages are the distance from the current price.
A snapshot of STRO market posture derived from its technical indicators and recent volatility. Higher trend and alignment lean bullish; higher risk means larger swings.
Technical Analysis
Indicators computed on daily closing prices.
| Period | SMA | Action | EMA | Action |
|---|---|---|---|---|
| MA 5 | $30.86 | Sell | $30.56 | Sell |
| MA 10 | $31.21 | Sell | $30.66 | Sell |
| MA 20 | $30.20 | Sell | $30.39 | Sell |
| MA 50 | $31.67 | Sell | $29.94 | Buy |
| MA 100 | $28.28 | Buy | $27.29 | Buy |
| MA 200 | $19.55 | Buy | $22.94 | Buy |
| Name | Value | Action |
|---|---|---|
| RSI (14) | 48.06 | Neutral |
| Stoch RSI (14) | 0.00 | Buy |
| CCI (20) | -26.18 | Neutral |
| Williams %R (14) | -87.02 | Info |
| MACD (12,26,9) | 0.05 | Buy |
| ROC (12) | 1.85 | Buy |
| Bollinger %B (20,2) | 0.43 | Neutral |
| Stochastic %K (14) | 12.98 | Buy |
| TRIX (15) | 0.06 | Buy |
| Awesome (5,34) | 1.80 | Buy |
| Ultimate (7,14,28) | 36.51 | Neutral |
| Momentum (10) | 0.18 | Buy |
| Aroon Osc (25) | 56.00 | Buy |
| Hull MA (9) | 30.61 | Sell |
| ADX (14) | 10.50 | Neutral |
| ATR (14) | 1.21 | Info |
The 30-day technical picture currently shows sentiment as BULLISH with an RSI(14) of 50. The 50-day simple moving average is $32.10 and the 200-day simple moving average is $18.89, outlining a positive near-term trend. The stock’s near-term support sits at $24.43 and resistance at $33.35, framing a typical range for recent volatility.
The 30-day range spans from $21.57 to $42.40, reflecting a wide trading band and the potential for price movement within that window.
| Year | Min | Avg | Max | ROI | Sentiment |
|---|---|---|---|---|---|
| $10.63 | $29.99 | $47.79 | 0% | Neutral | |
| $30.31 | $40.53 | $58.35 | +35% | Bullish | |
| $31.11 | $43.72 | $66.56 | +46% | Bullish | |
| $31.54 | $46.23 | $73.46 | +54% | Bullish | |
| $36.45 | $55.48 | $91.38 | +85% | Bullish | |
| $43.23 | $68.14 | $115.75 | +127% | Bullish | |
| $52.12 | $84.93 | $148.27 | +183% | Bullish | |
| $61.90 | $104.10 | $186.27 | +247% | Bullish | |
| $58.36 | $101.18 | $185.17 | +237% | Bullish | |
| $56.15 | $100.27 | $187.36 | +234% | Bullish | |
| $82.61 | $169.69 | $345.46 | +466% | Bullish | |
| $201.44 | $447.64 | $1,029.03 | +13.9x | Bullish |
Current year — the forecast is anchored to the live price, so ROI shows 0%.
| Month | Min | Avg | Max | Change |
|---|---|---|---|---|
| July 2026 | $10.63 | $29.99 | $35.77 | +0.00% |
| August 2026 | $25.39 | $30.52 | $38.04 | +1.76% |
| September 2026 | $27.19 | $33.07 | $41.96 | +8.35% |
| October 2026 | $27.61 | $33.92 | $43.68 | +2.57% |
| November 2026 | $27.54 | $34.12 | $44.49 | +0.60% |
| December 2026 | $29.01 | $36.24 | $47.79 | +6.21% |
Click any year to see its month-by-month STRO forecast. Min / Avg / Max are a bear / base / bull scenario; ROI is the projected move from the current price. Change is the month-over-month move in the average. Estimates, not guarantees.
Expect STRO to range from $10.63 to $47.79 through 2026. The $29.99 average target implies a 0% move from current prices. A consolidation phase looks the most probable path here.
The STRO price prediction for 2027 points to an average of $40.53 (low $30.31, high $58.35) — a potential gain of +35% on today's $29.99. Momentum favours further upside here.
In 2028, STRO is projected to trade between $31.11 and $66.56, averaging $43.72 — a potential gain of +46% from today's $29.99. That is up +8% on the projected 2027 average. Buyers look set to stay in control over this stretch.
Sutro Biopharma, Inc.'s 2029 outlook centres on $46.23, within a $31.54 to $73.46 range. That is up +6% on the projected 2028 average. That marks a +54% change versus current levels. Momentum favours further upside here.
By 2030, STRO could reach as high as $91.38, with a base case around $55.48 and support toward $36.45 — roughly +85% from $29.99. Buyers look set to stay in control over this stretch.
Expect STRO to range from $43.23 to $115.75 through 2031. The $68.14 average target implies a +127% move from current prices. That is up +23% on the projected 2030 average. Momentum favours further upside here.
The STRO price prediction for 2032 points to an average of $84.93 (low $52.12, high $148.27) — a potential gain of +183% on today's $29.99. Buyers look set to stay in control over this stretch.
In 2033, STRO is projected to trade between $61.90 and $186.27, averaging $104.10 — a potential gain of +247% from today's $29.99. That is up +23% on the projected 2032 average. Momentum favours further upside here.
Sutro Biopharma, Inc.'s 2034 outlook centres on $101.18, within a $58.36 to $185.17 range. That is -3% versus the projected 2033 average. That marks a +237% change versus current levels. Buyers look set to stay in control over this stretch.
By 2035, STRO could reach as high as $187.36, with a base case around $100.27 and support toward $56.15 — roughly +234% from $29.99. Momentum favours further upside here.
Expect STRO to range from $82.61 to $345.46 through 2040. The $169.69 average target implies a +466% move from current prices. That is up +69% on the projected 2035 average. Buyers look set to stay in control over this stretch.
The STRO price prediction for 2050 points to an average of $447.64 (low $201.44, high $1,029.03) — a potential gain of +13.9x on today's $29.99. Momentum favours further upside here.
Investing $1,000 in STRO today (≈ 33.344448 STRO) could be worth
$14,926.35
+$13,926.35 (+1393%) by 2050 · US Dollar
Based on the average projected STRO price of $447.64 in 2050.
Based on the base (average) forecast scenario. FX rates are indicative. Estimates only — not financial advice.
See what a past investment in STROwould be worth at today's price.
$1,000 invested in STRO on Jul 10, 2025 (≈ 121.951222 STRO) would be worth
$3,657.32
+$2,657.32 (+265.7%) today · 3.66× · US Dollar
Based on a STRO entry price of $8.2 vs. today's $29.99.
| Invested | Entry price | Value today | Return |
|---|---|---|---|
| 1 week ago | $30.43 | $985.54 | -1.4% |
| 1 month ago | $26.09 | $1,149.48 | +14.9% |
| 3 months ago | $25.86 | $1,159.71 | +16.0% |
| 6 months ago | $11.33 | $2,646.96 | +164.7% |
| 1 year ago | $8.2 | $3,657.32 | +265.7% |
| All time (5.0y) ago | $178.8 | $167.73 | -83.2% |
Past performance from historical market data — it does not predict future results. FX rates are indicative. Not financial advice.
Enter a price to see how it sits against our STRO forecast.
Our base-case forecast reaches $60.00 around 2031.
Implied market cap at $60.00: $994.23M
The multi-year forecast points to a steadily higher average price with a clearly bullish trajectory after 2026. In 2026 the average is $30.24 with a neutral sentiment and no ROI indicated in the forecast. By 2027 the average rises to $41.19 with a 36.2% ROI and a bullish sentiment, followed by 2028 at $45.86 (51.6% ROI) and 2029 at $50.21 (66% ROI).
By 2030 the average is $59.77 and the ROI is 97.6% with a bullish outlook. The forecast continues to show strength into subsequent years, with 2031 at $78.65 (160.1% ROI) and 2032 at $100.41 (232% ROI); 2033 at $121.28 (301.1% ROI) and 2034 at $118.34 (291.3% ROI); 2035 at $117.34 (288% ROI). The long-range view extends to 2040 with an average of $208.03 and a 587.9% ROI, then to 2050 with an average of $608.26 and a 1911.4% ROI, all labeled bullish.
These numbers illustrate substantial upside potential over the long term, though these are estimates and not guarantees. The path depends on factors not specified here, and actual results may differ from the projected averages and returns.
Tap a question to reveal the answer.
The forecast shows an average price of $59.77 with a min of $37.50, a max of $102.45; ROI 97.6%; sentiment BULLISH.
The 2027 average is $41.19, rising through 2028 ($45.86) and 2029 ($50.21) to 2030 ($59.77), with bullish sentiment and ROI of 36.2% in 2027, 51.6% in 2028, 66% in 2029, and 97.6% in 2030.
Yes, the forecast shows the 2030 max at $102.45, the 2032 max at $183.36, the 2040 max at $448.29, and the 2050 max at $1,398.99.
Current price is $30.24 and market cap is $501.09M.
RSI(14) is 50 and the sentiment is BULLISH. The 50-day SMA is $32.10 and the 200-day SMA is $18.89, with support at $24.43 and resistance at $33.35. The 30-day range is $21.57 to $42.40.
Sutro Biopharma, Inc. Community Discussion
0Share your Sutro Biopharma, Inc. price prediction and read what the community thinks. Be respectful — comments are public and not financial advice.
Be the first to share your prediction…
What's your take? Add a comment above to start the conversation.